Description of Invention:
The technology is directed to a method of inhibiting ABCG2, which is a multidrug resistance (MDR) protein. It is believed that ABCG2 plays a role in the development of resistance of cancer cells to chemotherapeutics. Therefore, inhibition of ABCG2 would allow chemotherapeutics to be more effective in killing cancer cells, thereby treating cancer. Five compounds were identified in the provisional application that inhibit ABCG2. These compounds are known in the literature and are part of the NCI Developmental Therapeutics Program (DTP).
Applications:
Cancer therapeutics
Research tools to study function of ABCG2 proteins
Advantages:
Valuable tools to further developing understanding or normal and cancer cells
Augment efficacy of drugs that are ABCG2 substrates
Development Status:
Early stage
Market:
Cancer is the second leading cause of death in America, after heart disease. Multiple drug resistance is a significant impediment in the treatment of cancers resulting in a poor prognosis. The market for effective cancer treatments is very large.
Patent Status:
DHHS Reference No. E-316-2007/0 --
U.S. Provisional Application No. 60/986,155 filed 07 Nov 2007
Licensing Status: Available for exclusive or non-exclusive licensing.
Collaborative Research Opportunity:
The National Cancer Institute Molecular Targets Development Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Method of Inhibiting ABCG2 and Related Treatments. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
Portfolios: Cancer
Cancer -Therapeutics Cancer -Research Materials
For Additional Information Please Contact: Sabarni K. Chatterjee Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-5587
Email: chatterjeesa@mail.nih.gov
Fax: 301/402-0220
